Cargando…

Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism

Constitutive signaling through the phosphatidylinositol-3-kinase-Akt-mechanistic target of rapamycin (PI3K-Akt-mTOR) pathway is present in acute myeloid leukemia (AML) cells. However, AML is a heterogeneous disease, and we therefore investigated possible associations between cellular metabolism and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nepstad, Ina, Reikvam, Håkon, Brenner, Annette K., Bruserud, Øystein, Hatfield, Kimberley J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5855604/ https://www.ncbi.nlm.nih.gov/pubmed/29382066 http://dx.doi.org/10.3390/ijms19020382

Ejemplares similares

Correction: Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells
por: Reikvam, Håkon, et al.
Publicado: (2017)

Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis
por: Nepstad, Ina, et al.
Publicado: (2018)

Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells
por: Reikvam, Håkon, et al.
Publicado: (2013)

The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells
por: Nepstad, Ina, et al.
Publicado: (2020)

Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells
por: Nepstad, Ina, et al.
Publicado: (2019)

Inhibition of Mammalian Target of Rapamycin in Human Acute Myeloid Leukemia Cells Has Diverse Effects That Depend on the Environmental In Vitro Stress
por: Ryningen, Anita, et al.
Publicado: (2012)

Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms
por: Brenner, Annette K., et al.
Publicado: (2017)

Connexin expression in human acute myeloid leukemia cells: Identification of patient subsets based on protein and global gene expression profiles
por: REIKVAM, HÅKON, et al.
Publicado: (2015)

A Subset of Patients with Acute Myeloid Leukemia Has Leukemia Cells Characterized by Chemokine Responsiveness and Altered Expression of Transcriptional as well as Angiogenic Regulators
por: Brenner, Annette K., et al.
Publicado: (2016)

The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells
por: Brenner, Annette K., et al.
Publicado: (2016)

The pretransplant systemic metabolic profile reflects a risk of acute graft versus host disease after allogeneic stem cell transplantation
por: Reikvam, Håkon, et al.
Publicado: (2015)

Toll-like Receptor 4, Osteoblasts and Leukemogenesis; the Lesson from Acute Myeloid Leukemia
por: Bruserud, Øystein, et al.
Publicado: (2022)

Pretransplant Systemic Lipidomic Profiles in Allogeneic Stem Cell Transplant Recipients
por: Hatfield, Kimberley Joanne, et al.
Publicado: (2022)

Acute Myeloid Leukemia with the t(8;21) Translocation: Clinical Consequences and Biological Implications
por: Reikvam, Håkon, et al.
Publicado: (2011)

Therapeutic Targeting the Cell Division Cycle 25 (CDC25) Phosphatases in Human Acute Myeloid Leukemia — The Possibility to Target Several Kinases through Inhibition of the Various CDC25 Isoforms
por: Brenner, Annette K., et al.
Publicado: (2014)

Future Perspectives: Therapeutic Targeting of Notch Signalling May Become a Strategy in Patients Receiving Stem Cell Transplantation for Hematologic Malignancies
por: Ersvaer, Elisabeth, et al.
Publicado: (2011)

Cytokines, Adhesion Molecules, and Matrix Metalloproteases as Predisposing, Diagnostic, and Prognostic Factors in Venous Thrombosis
por: Mosevoll, Knut A., et al.
Publicado: (2018)

The Possible Importance of β3 Integrins for Leukemogenesis and Chemoresistance in Acute Myeloid Leukemia
por: Johansen, Silje, et al.
Publicado: (2018)

Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia
por: Bruserud, Øystein, et al.
Publicado: (2023)

Targeting Cellular Metabolism in Acute Myeloid Leukemia and the Role of Patient Heterogeneity
por: Grønningsæter, Ida Sofie, et al.
Publicado: (2020)

Endocan in Acute Leukemia: Current Knowledge and Future Perspectives
por: Reikvam, Håkon, et al.
Publicado: (2022)

Preconditioning Serum Levels of Endothelial Cell-Derived Molecules and the Risk of Posttransplant Complications in Patients Treated with Allogeneic Stem Cell Transplantation
por: Lindås, Roald, et al.
Publicado: (2014)

Metabolic Serum Profiles for Patients Receiving Allogeneic Stem Cell Transplantation: The Pretransplant Profile Differs for Patients with and without Posttransplant Capillary Leak Syndrome
por: Reikvam, Håkon, et al.
Publicado: (2015)

In Vitro Characterization of Valproic Acid, ATRA, and Cytarabine Used for Disease-Stabilization in Human Acute Myeloid Leukemia: Antiproliferative Effects of Drugs on Endothelial and Osteoblastic Cells and Altered Release of Angioregulatory Mediators by Endothelial Cells
por: Kvestad, Hilde, et al.
Publicado: (2014)

CDC25 Inhibition in Acute Myeloid Leukemia–A Study of Patient Heterogeneity and the Effects of Different Inhibitors
por: Brenner, Annette K., et al.
Publicado: (2017)

Effects of the Autophagy-Inhibiting Agent Chloroquine on Acute Myeloid Leukemia Cells; Characterization of Patient Heterogeneity
por: Grønningsæter, Ida Sofie, et al.
Publicado: (2021)

Myeloid Sarcoma after Allogenic Stem Cell Transplantation for Acute Myeloid Leukemia: Successful Consolidation Treatment Approaches in Two Patients
por: Johansen, Silje, et al.
Publicado: (2018)

Patients with Treatment-Requiring Chronic Graft versus Host Disease after Allogeneic Stem Cell Transplantation Have Altered Metabolic Profiles due to the Disease and Immunosuppressive Therapy: Potential Implication for Biomarkers
por: Reikvam, Håkon, et al.
Publicado: (2018)

Patient Heterogeneity in Acute Myeloid Leukemia: Leukemic Cell Communication by Release of Soluble Mediators and Its Effects on Mesenchymal Stem Cells
por: Aasebø, Elise, et al.
Publicado: (2021)

High Constitutive Cytokine Release by Primary Human Acute Myeloid Leukemia Cells Is Associated with a Specific Intercellular Communication Phenotype
por: Reikvam, Håkon, et al.
Publicado: (2019)

Effects of cytarabine on activation of human T cells – cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid
por: Ersvaer, Elisabeth, et al.
Publicado: (2015)

The Possible Diagnostic and Prognostic Use of Systemic Chemokine Profiles in Clinical Medicine—The Experience in Acute Myeloid Leukemia from Disease Development and Diagnosis via Conventional Chemotherapy to Allogeneic Stem Cell Transplantation
por: Reikvam, Håkon, et al.
Publicado: (2013)

Clinical proteomics of myeloid leukemia
por: Hjelle, Sigrun M, et al.
Publicado: (2010)

S100 Proteins in Acute Myeloid Leukemia()()
por: Brenner, Annette K., et al.
Publicado: (2018)

Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation
por: Reikvam, Håkon, et al.
Publicado: (2018)

Heterogeneity of Patient-Derived Acute Myeloid Leukemia Cells Subjected to SYK In Vitro Inhibition
por: Brattås, Marte Karen, et al.
Publicado: (2022)

Critical upper airway obstruction as the first symptom of acute myeloid leukemia - an anesthesiologic reminder
por: Bruserud, Øyvind, et al.
Publicado: (2020)

Therapeutic Use of Valproic Acid and All-Trans Retinoic Acid in Acute Myeloid Leukemia—Literature Review and Discussion of Possible Use in Relapse after Allogeneic Stem Cell Transplantation
por: Bruserud, Øystein, et al.
Publicado: (2021)

Proteomic Studies of Primary Acute Myeloid Leukemia Cells Derived from Patients Before and during Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid and Valproic Acid
por: Hernandez-Valladares, Maria, et al.
Publicado: (2021)

Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia – identification of responders by gene expression profiling of pretreatment leukemic cells
por: Reikvam, Håkon, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8g59v2evusl2s9u7h8mg5i5pkm